The Dermatology Digest

JUNE 5, 2024

Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. “In

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. Senior Vice President and Chief Research & Development Officer at Nektar, in a news release.

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

MARCH 5, 2025

This is a great milestone for our team, as we continue to examine the acne market, we believe there is still a high unmet need by patients for an acne product like XYNGARI, says Gerry Proehl, Dermatas Chairman, President, and Chief Executive Officer, in a news release.

Treatments 36

Treatments Rosacea Pores Office 36

New Age Spa Institute

NOVEMBER 20, 2024

Licenses like those for esthetics, cosmetology , and massage therapy give professionals the legal right to practice their craft and offer services to the public. Choosing Between Esthetics, Cosmetology & Massage Therapy One of the most common questions we hear is, “ What’s the difference between an esthetician and a cosmetologist?

Esthetics 52

Esthetics Therapy Continuous Education Continuing Education 52

The Dermatology Digest

FEBRUARY 11, 2025

. “We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. “Further, based on the clinical characteristics of bempikibart, we continue to believe there is potential utility across additional autoimmune conditions.

Clinic 36

Clinic Therapy Office Tools 36

US Dermatologt Partners

MARCH 27, 2024

Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. What is Red Light Therapy? According to Dr. Jean Charles of U.S.

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

Aesthetics Advisor

JULY 4, 2024

In recent years, the allure of IV drip therapy has surged, captivating both health enthusiasts and celebrities alike. In an exploration of the scientific realms of IV drip therapy, we talked to Dr. Anant Vinjamoori, MD, Chief Medical Officer of Modern Age and Harvard-trained longevity expert. What is IV drip therapy?

Therapy 36

Therapy Vitamin C Injections Medical 36

Aesthetics Advisor

FEBRUARY 9, 2024

One of the most promising approaches in cellular therapies is immunotherapies using engineered T cells or natural killer (NK) cells expressing chimeric antigen receptors (CARs). Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? What is CAR-T? What is CAR-NK?

Therapy 36

Therapy Office Safety Treatments 36

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

DECEMBER 14, 2023

The study included 30 patients with ≥3% BSA who have been on stable biologic therapy for at least 26 weeks. Patients returned at week 16 to assess safety and evaluate maintenance response. ” Moreover, Vtama cream was well tolerated, with no new safety signals when used in combination with injectable biologics.

Injections 36

Injections Safety Office Therapy 36

The Dermatology Digest

APRIL 17, 2024

The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CIndU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy.

Safety 36

Safety Injections Office Therapy 36

The Dermatology Digest

JULY 22, 2024

“We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

New Age Spa Institute

DECEMBER 19, 2023

To Qualify for an Massage Therapy License, what’s needed? Massage Therapy License candidates need a high school diploma or GED and must complete fingerprints and a criminal background check. How To Start a Massage Therapist Career What happens after completing your massage therapy program and obtaining your license?

Private Practice 40

Private Practice Ethics Therapy Education 40

The Dermatology Digest

FEBRUARY 6, 2024

The sNDA is supported by two clinical phase I studies investigating the safety of the application of three tubes of Ameluz. Further to a Type A meeting with the FDA in 2021, an additional safety trial with 100 patients receiving PDT with three tubes of Ameluz was conducted.

Safety 28

Safety Office Ingredients Therapy 28

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

MAY 9, 2024

Of the eight responding patients from GEMINI-1 who were re-randomized to monthly 200mg SC imsidolimab maintenance therapy, 100% maintained a GPPPGA score of 0/1 and none of them experienced a flare. PhD, chief medical officer of Anaptys. What’s Next for IL-36R mAb? PHOTO CREDIT: DermNet The post AnaptysBio, Inc.’s

Office 36

Office Medical Safety Therapy 36

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. Chief Executive Officer of Apogee, in a news release. . Chief Executive Officer of Apogee, in a news release. “We

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

DECEMBER 19, 2023

The primary endpoint of the clinical trial was safety and tolerability. No patients experienced flare requiring rescue therapy. Brady, MD, PhD, President and Chief Executive Officer of Aldeyra. The open-label, single-center Phase 2 clinical trial of ADX-629 included eight mild-to-moderate AD patients.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

FEBRUARY 13, 2024

EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds that is currently in the advanced stages of clinical development. The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0 days for Santyl.

Safety 36

Safety Marketing Office Clinic 36

The Dermatology Digest

JUNE 28, 2021

Cabenuva greatly simplifies an HIV treatment regimen while facilitating the healthcare provider’s monitoring adherence to an antiretroviral treatment regimen by injecting the patient in the office. of patients in the oral therapy group had HIV-1 RNA levels ≥ 50 copies/mL, for an adjusted difference of 0.6% (95% confidence interval [CI]: 1.2

Injections 36

Injections Therapy Treatments Office 36

The Dermatology Digest

OCTOBER 5, 2023

Barr, MD, dual board-certified integrative dermatologist, certified somatic trauma therapy practitioner, Somatic Skin Science, Seattle, Washington. “It The DNA Connection Deep in our DNA, there’s a primordial theme of slowing down, connection, and safety, said Dr. Barr. Oftentimes we feel like something is coming at us.

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

MAY 15, 2024

alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. COVE-1 was an open label clinical trial that evaluated the safety and efficacy of VP-102 in two cohorts of subjects with up to six warts. With a prevalence of approximately 22 million patients in the U.S.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

Fairlawn Aesthetic MD

MARCH 14, 2024

Part of this personalized approach includes being upfront about who will most benefit from semaglutide/NAD+ therapy – and, importantly, who may not. Pregnancy or Nursing: The safety of semaglutide for pregnant women and nursing mothers is still under study, so we prefer to err on the side of caution.

Injections 36

Injections Management Medical Office 36

Aesthetics Advisor

JUNE 16, 2024

As with so many skin-care trends that have come before, this one is rooted in medicine — in this case, regenerative medicine, which is centered on developing and applying therapies to help the body heal itself. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.”

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

The Dermatology Digest

AUGUST 14, 2024

The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. It’s very, very exciting data.”

Pharmaceutical 36

Pharmaceutical Safety Clinic Dermatology 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4%

Dermatitis 36

Dermatitis Safety Office Eczema 36

Aesthetics Advisor

AUGUST 18, 2023

That's what got me on the path and that led me into learning about ozone and laser therapy and it really opened up a whole new world for me in the field of endodontics." Go to Fotona's website and find someone in your area using this laser therapy." One is ozone therapy. Another is laser therapy. That's a window.

Extractions 36

Extractions Technology Therapy Training 36

The Dermatology Digest

AUGUST 4, 2023

They extrapolated that across 15 million office visits. 1 Explanations for the decline included poor compliance, poor reimbursement, fear of skin cancer, and the promise of newer therapies, said Dr. Richard. Many patients are not medical or financial candidates for biologic or oral therapy, said Dr. Richard.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

First Derm

NOVEMBER 25, 2023

Relationship impact : honesty and safety measures are key. 20] The American College of Obstetricians and Gynecologists (ACOG) emphasizes the significant morbidity and mortality caused by HPV and strongly recommends HPV vaccination to eligible patients, stressing the benefits and safety of the vaccine. Advances in Therapy.

Safety 45

Safety Education Clinic Therapy 45

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

NOVEMBER 20, 2024

The approval of bimekizumab-bkzx blocker is supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS. living with moderate-to-severe disease,” says Brindley Brooks, Founder and Executive Director of HS Connect.

Safety 78

Safety Sustainability Clinic Medical 78

The Dermatology Digest

FEBRUARY 24, 2025

Safety and tolerability results were consistent with previous trials of roflumilast cream 0.15% in patients aged 6 years with AD. The most frequent adverse events in the roflumilast cream arm (2%) included upper respiratory tract infection, diarrhea, and vomiting. All individual AEs occurred in <4.1% of patients.

Eczema 67

Eczema Dermatitis Safety Dermatology 67

Aesthetics Advisor

OCTOBER 7, 2023

The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. First Line Therapies (In order of priority; not all required.) Disclaimer: This protocol is solely for educational purposes regarding potentially beneficial therapies for COVID-19.

Treatments 69

Treatments Therapy Medical Vitamin C 69